Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

17.12.24 12:00 Uhr

Werte in diesem Artikel

DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.

Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)

To request a one-on-one meeting with the Theravance Biopharma management team, please contact us at investor.relations@theravance.com.

About Theravance Biopharma 

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-conduct-investor-meetings-during-the-jp-morgan-43rd-annual-healthcare-conference-302333431.html

SOURCE Theravance Biopharma, Inc.

Ausgewählte Hebelprodukte auf Theravance Biopharma

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Theravance Biopharma

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Theravance Biopharma Inc When Issued

Analysen zu Theravance Biopharma Inc When Issued

DatumRatingAnalyst
16.06.2017Theravance Biopharma OverweightCantor Fitzgerald
11.05.2017Theravance Biopharma BuyNeedham & Company, LLC
21.12.2016Theravance Biopharma BuyNeedham & Company, LLC
12.10.2016Theravance Biopharma UnderperformRobert W. Baird & Co. Incorporated
03.02.2015Theravance Biopharma NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
16.06.2017Theravance Biopharma OverweightCantor Fitzgerald
11.05.2017Theravance Biopharma BuyNeedham & Company, LLC
21.12.2016Theravance Biopharma BuyNeedham & Company, LLC
DatumRatingAnalyst
03.02.2015Theravance Biopharma NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
12.10.2016Theravance Biopharma UnderperformRobert W. Baird & Co. Incorporated

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Theravance Biopharma Inc When Issued nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"